It seems like a "we're not in Kansas anymore" moment. The validity of Merck & Co., Inc.’s patents for its 16-year old blockbuster diabetes treatment Januvia (sitagliptin) were upheld by a US district court 29 September, bolstering market exclusivity for the drug until May 2027.
Merck’s Januvia, Medicare Pricing, And The Meaning of Patent Life
Recent patent extension win for Januvia illustrates the dilemma that will be faced by manufacturers of older, single-source drugs that are chosen for price negotiation in the Medicare program.
